Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM) was held in Charleston, SC, on October 23-25, 2024. The workshop brought together leading myeloma experts to share the latest advances in high-risk disease. iwHRMM 2024 is supported by Johnson & Johnson, Arcellx, Sanofi, GSK and Legend Biotech. Supporters have no influence over the production of the content.
iwHRMM 2024
The 1st International Workshop on High-Risk Multiple Myeloma
23–25 October 2024 | Charleston, SC
The 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM) was held in Charleston, SC, on October 23-25, 2024. The workshop brought together leading myeloma experts to share the latest advances in high-risk disease. iwHRMM 2024 is supported by Johnson & Johnson, Arcellx, Sanofi, GSK and Legend Biotech. Supporters have no influence over the production of the content.
View all videos
Explore roundtable discussions from this year's workshop
View all videos
Defining high-risk MM
Extramedullary disease biology
MMSET disease subset
Circulating malignant plasma cell biology
Immuno- and targeted therapies and data in high-risk – Part 1
Immuno- and targeted therapies and data in high-risk – Part 2
CAR therapies and data in high-risk
MAF/MAFB disease
Designing single-arm studies in high-risk MM
Designing randomized studies in high-risk MM
Session 1: Defining high-risk MM
New classification for identifying high-risk multiple myeloma based on cytogenetic abnormalities
Faith Davies NYU Langone Health, New York City, NY, United States
Using genomics to predict high-risk multiple myeloma
Francesco Maura Memorial Sloan Kettering Cancer Center, New York, NY, United States
Too much for T cells! What defines high-risk disease in the era of T-cell redirecting therapy?
Simon Harrison Peter MacCallum Cancer Centre, Melbourne, Australia
Frailty: A high-risk feature in MM
Hira Mian McMaster University, Hamilton, Canada
Future directions in defining HRMM by genomics, immunomics, and microenvironment
Kenneth Anderson Dana-Farber Cancer Institute, Boston, MA, United States
Definition and outcomes of high-risk multiple myeloma in recent clinical trials
Pieter Sonneveld Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
Session 2: Extramedullary disease biology
Extramedullary disease versus paramedullary disease Part 1 – is there a biological difference?
Faith Davies NYU Langone Health, New York City, NY, United States
Extramedullary disease versus paramedullary disease Part 2
Kylee Maclachlan Memorial Sloan Kettering Cancer Center, New York, NY, United States
Stromal interaction related gene expression changes recapitulate the transcriptional program of extramedullary disease
Mehmet Samur Dana-Farber Cancer Institute, Boston, MA, United States
The role of imaging in the management of extramedullary disease
Elena Zamagni University of Bologna, Bologna, Italy
Session 3: MMSET disease subset
Direct and indirect targeting of MMSET in t(4;14) myeloma
Jonathan Licht UF Health Cancer Center, Gainesville, FL, United States
Prognostic impact of t(4;14), alone and in combination with other genomic risk factors
Kylee Maclachlan Memorial Sloan Kettering Cancer Center, New York, NY, United States
Targeting epigenetic dysregulation in t(4;14) multiple myeloma
Benjamin Barwick Winship Cancer Institute of Emory University, Atlanta, GA, United States
Session 4: Circulating malignant plasma cell biology
Genomics drivers of the adverse biology of circulating plasma cells
Gareth Morgan NYU Langone Health, New York City, NY, United States
Circulating tumor cells in multiple myeloma
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States
The potential of liquid biopsies to track and understand disease dissemination
Juan José Garcés Memorial Sloan Kettering Cancer Center, New York, NY, United States
Session 5: Immuno- and targeted therapies and data in high-risk – Part 1
Do bispecifics work better for any high-risk subsets?
Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States
How to optimize bispecific antibodies for better outcomes in high-risk MM
Ajai Chari University of California San Francisco (UCSF), San Francisco, CA, United States
Resistance to bispecific antibodies: high-risk immune profile
Niels van de Donk VU University Medical Center, Amsterdam, Netherlands
Session 6: Immuno- and targeted therapies and data in high-risk – Part 2
Novel approaches to overcome high-risk myeloma
Samir Parekh Icahn School of Medicine at Mount Sinai, New York, NY, United States
The role of CELMoDs in management of high-risk disease
Nisha Joseph Emory University School of Medicine, Atlanta, GA, United States
The role of ADCs in the management of high-risk myeloma
Peter Voorhees Levine Cancer Institute, Atrium Health, Charlotte, NC, United States
Session 7: CAR therapies and data in high-risk
CAR T-cell therapy for functional high-risk patients: suboptimal responders and early relapse
Roberto Mina University of Turin, Turin, Italy
Does CAR T-cell therapy work for patients with EMD, PCL, CNS disease and other high-risk features? Is one-and-done the right approach?
Krina Patel The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 8: MAF/MAFB disease
Immune microenvironment changes driven by high-risk genetic lesions across MM subtypes
José Martínez-Climent University of Navarra, Pamplona, Spain
C-eeing a MAF or B-eing A-MAF phenotype variant
Jonathan Keats TGen, Phoenix, AZ, United States
Session 9: Designing single-arm studies in high-risk MM
Incorporating novel therapies and innovative trial designs for high-risk, newly diagnosed multiple myeloma
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Maximizing the activity of cell-cycle specific chemotherapy to treat HRMM
Leif Bergsagel Mayo Clinic, Phoenix, AZ, United States
Bispecific antibody-based combination therapy for high-risk TE-ND MM
Marc Raab Heidelberg Myeloma Center, Heidelberg, Germany
External comparator arm trials for high-risk myeloma patients: the OPTIMUM/MUKnine experience
Martin Kaiser The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
Session 10: Designing randomized studies in high-risk MM
Practical aspects in designing randomized studies in high-risk MM
Francesca Gay University of Turin, Turin, Italy
Early immunotherapy deployment to overcome biologic and dynamic high-risk multiple myeloma
Binod Dhakal Medical College of Wisconsin, Milwaukee, WI, United States
Creating global academic trials in high-risk MM
Shaji Kumar Mayo Clinic, Rochester, MN, United States
iwHRMM 2024 has been supported by:
